NYSE, BMY - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb,
BMS or the Company) was incorporated under the laws of the State of Delaware in
August 1933 under the name Bristol-Myers Company, as successor to a New York
business started in 1887. In 1989, Bristol-Myers Company changed its name to
Bristol-Myers Squibb Company as a result of a merger. The Company, through its
divisions and subsidiaries, is engaged in the discovery, development, licensing,
manufacturing, marketing, distribution and sale of pharmaceuticals and other
health care related products.
Acquisitions and Divestitures
In July 2007, the Company completed the sale of the BUFFERIN* and EXCEDRIN*
brands in Japan, Asia (excluding China and Taiwan) and certain Oceanic countries
to Lion Corporation (Japan) for $247 million in cash. As a result of this
transaction, the Company recognized a pre-tax gain of $247 million ($144 million
net of tax) in the third quarter of 2007. ...
Read SEC Filing on NASDAQ.com »